Oppenheimer Says Chemed (CHE) Remains Attractive
Tweet
Share
E-mailGet Alerts CHE Hot Sheet
Price: $541.23 +1.03%
Rating Summary:
1 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Rating Summary:
1 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Join SI Premium – FREE
Oppenheimer maintained an Outperform rating on Chemed (NYSE: CHE) and increased its price target to $80.00 (from $75.00). Chemed operates two wholly owned subsidiaries, Vitas Healthcare and RotoRooter.
After attending a meeting with Chemed management, analysts said they continue to believe Chemed remains an attractive stock to own heading into '13.
"On the hospice side, the business remains well positioned, as reimbursement risks remain low, particularly as lawmakers look for ways to control healthcare costs. Meanwhile, Roto-Rooter continues to provide solid cash flow, which could be applied toward future acquisitions," said analyst Michael Wiederhorn.
For an analyst ratings summary and ratings history on Chemed click here. For more ratings news on Chemed click here.
Shares of Chemed closed at $70.15 yesterday.
After attending a meeting with Chemed management, analysts said they continue to believe Chemed remains an attractive stock to own heading into '13.
"On the hospice side, the business remains well positioned, as reimbursement risks remain low, particularly as lawmakers look for ways to control healthcare costs. Meanwhile, Roto-Rooter continues to provide solid cash flow, which could be applied toward future acquisitions," said analyst Michael Wiederhorn.
For an analyst ratings summary and ratings history on Chemed click here. For more ratings news on Chemed click here.
Shares of Chemed closed at $70.15 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results
- SentinelOne Inc (S) PT Raised to $26 at Cantor Fitzgerald Following Strong Q2 Checks
- Rubrik Inc (RBRK) PT Raised to $120 at Oppenheimer; Sees Another 'Beat and Raise'
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
